MX2008015529A - Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn. - Google Patents
Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.Info
- Publication number
- MX2008015529A MX2008015529A MX2008015529A MX2008015529A MX2008015529A MX 2008015529 A MX2008015529 A MX 2008015529A MX 2008015529 A MX2008015529 A MX 2008015529A MX 2008015529 A MX2008015529 A MX 2008015529A MX 2008015529 A MX2008015529 A MX 2008015529A
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotide
- process according
- seq
- bacteriophage
- virus
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 74
- 239000002245 particle Substances 0.000 title claims abstract description 52
- 241001515965 unidentified phage Species 0.000 title claims abstract description 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract description 6
- 238000004806 packaging method and process Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 239000011248 coating agent Substances 0.000 claims description 26
- 238000000576 coating method Methods 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 8
- 101710132601 Capsid protein Proteins 0.000 claims description 4
- 101710094648 Coat protein Proteins 0.000 claims description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 4
- 101710125418 Major capsid protein Proteins 0.000 claims description 4
- 101710141454 Nucleoprotein Proteins 0.000 claims description 4
- 101710083689 Probable capsid protein Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 238000001338 self-assembly Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims 20
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 4
- 108091081548 Palindromic sequence Proteins 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 229940029575 guanosine Drugs 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 3
- 238000011534 incubation Methods 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 241000709737 Enterobacteria phage GA Species 0.000 claims 2
- 241000709738 Enterobacteria phage fr Species 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 238000010979 pH adjustment Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241001672158 Acinetobacter phage AP205 Species 0.000 claims 1
- 241001278075 Enterobacteria phage MX1 Species 0.000 claims 1
- 241001278054 Enterobacteria phage NL95 Species 0.000 claims 1
- 241000709747 Enterobacteria phage R17 Species 0.000 claims 1
- 101000742439 Enterobacteria phage T4 Head formation protein Proteins 0.000 claims 1
- 241000709739 Enterobacteria phage f2 Species 0.000 claims 1
- 241000709744 Enterobacterio phage MS2 Species 0.000 claims 1
- 241000709749 Pseudomonas phage PP7 Species 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 239000006096 absorbing agent Substances 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 210000000234 capsid Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81259206P | 2006-06-12 | 2006-06-12 | |
| PCT/EP2006/069734 WO2007068747A1 (en) | 2005-12-14 | 2006-12-14 | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| PCT/EP2007/005188 WO2007144150A1 (en) | 2006-06-12 | 2007-06-12 | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008015529A true MX2008015529A (es) | 2009-01-13 |
Family
ID=40243628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008015529A MX2008015529A (es) | 2006-06-12 | 2007-06-12 | Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8541559B2 (enExample) |
| EP (2) | EP2530086B1 (enExample) |
| JP (2) | JP5437797B2 (enExample) |
| KR (1) | KR101552227B1 (enExample) |
| CN (1) | CN101466720B (enExample) |
| AU (1) | AU2007260236B2 (enExample) |
| BR (1) | BRPI0713651B1 (enExample) |
| CA (1) | CA2655108C (enExample) |
| DK (1) | DK2032592T3 (enExample) |
| ES (2) | ES2738986T3 (enExample) |
| IL (1) | IL195526A (enExample) |
| MX (1) | MX2008015529A (enExample) |
| NZ (1) | NZ573622A (enExample) |
| PL (1) | PL2032592T3 (enExample) |
| PT (1) | PT2032592E (enExample) |
| RU (1) | RU2476595C2 (enExample) |
| SG (1) | SG172696A1 (enExample) |
| SI (1) | SI2032592T1 (enExample) |
| WO (1) | WO2007144150A1 (enExample) |
| ZA (1) | ZA200810109B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1812051A2 (en) | 2004-10-05 | 2007-08-01 | Cytos Biotechnology AG | Vlp-antigen conjugates and their uses as vaccines |
| SI2032592T1 (sl) | 2006-06-12 | 2013-10-30 | Cytos Biotechnology Ag | Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov |
| WO2008071774A1 (en) * | 2006-12-14 | 2008-06-19 | Cytos Biotechnology Ag | Purification process for coat protein of rna bacteriophages |
| US8088392B2 (en) * | 2007-06-18 | 2012-01-03 | Yunxu Cao | Capsid proteins and uses therefore |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| WO2015024992A2 (en) * | 2013-08-22 | 2015-02-26 | Cytos Biotechnology Ag | Treatment of asthma |
| HUE053145T2 (hu) | 2014-12-31 | 2021-06-28 | Checkmate Pharmaceuticals Inc | Kombinált tumor immunterápia |
| JP6875289B2 (ja) | 2015-04-06 | 2021-05-19 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 難溶性薬物伝達用の溶解性マイクロニドル |
| US20190046638A1 (en) | 2016-04-01 | 2019-02-14 | Checkmate Pharmaceuticals, Inc. | Fc RECEPTOR-MEDIATED DRUG DELIVERY |
| WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
| MX2019005502A (es) | 2016-11-09 | 2020-10-01 | Univ Texas | Metodos y composiciones para inmunomodulacion adaptativa. |
| WO2019160866A2 (en) | 2018-02-13 | 2019-08-22 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| BR112020020479A2 (pt) * | 2018-04-09 | 2021-01-12 | Checkmate Pharmaceuticals | Empacotamento de oligonucleotídeos em partículas similares a vírus |
| JP7625519B2 (ja) * | 2018-11-21 | 2025-02-03 | カリヴィル イムノセラピューティクス， インコーポレイテッド | ウイルスの製造 |
| AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| WO2025186318A2 (en) | 2024-03-06 | 2025-09-12 | Elanco Us Inc. | Veterinary compositions of modified virus-like particles of cmv and feline il-1beta mutein antigens |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2034118A1 (en) | 1970-07-09 | 1972-01-13 | Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München | Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5039813A (en) | 1990-06-29 | 1991-08-13 | Polaroid Corporation | 2-(4-alkenylphenyl)-5-oxazolones and polymers thereof |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| EP0563091A1 (en) | 1990-12-20 | 1993-10-06 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccines based on hepatitis b surface antigen |
| GB9101550D0 (en) | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
| GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| GB9213601D0 (en) | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
| JPH08502723A (ja) | 1992-07-27 | 1996-03-26 | ハイブライドン インコーポレイテッド | オリゴヌクレオチド・アルキルホスホノチオエート |
| FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| CN1185811A (zh) | 1995-03-31 | 1998-06-24 | H·沃尔夫 | 依赖于逆转录病毒样颗粒的抗原呈递系统 |
| US5994315A (en) | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
| CZ293584B6 (cs) | 1996-01-23 | 2004-06-16 | Icn Pharmaceuticals | Prostředek pro modulaci exprese lymfokinů |
| AU711536B2 (en) | 1996-01-24 | 1999-10-14 | Aliatros Medical A.S. | Composition for treating cancer containing a ribose compound, beta-alanine, ascorbic acid and nicotinic acid |
| CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| WO1998016247A1 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU7350798A (en) | 1997-04-29 | 1998-11-24 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
| AU750702B2 (en) | 1997-05-01 | 2002-07-25 | Chiron Corporation | Use of virus-like particles as adjuvants |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| WO1998055609A1 (en) | 1997-06-06 | 1998-12-10 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| EP1012173B1 (en) | 1997-06-23 | 2007-10-31 | Ludwig Institute For Cancer Research | Isolated decapeptides which bind to hla molecules, and the use thereof |
| DE19731784A1 (de) | 1997-07-24 | 1999-02-04 | Bayer Ag | Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide |
| US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
| PT1009413E (pt) | 1997-09-05 | 2007-05-31 | Univ California | Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma. |
| US6171591B1 (en) | 1997-12-08 | 2001-01-09 | Pentamer Pharmaceuticals, Inc. | Recombinant nodavirus compositions and methods |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
| AU760795B2 (en) | 1998-05-14 | 2003-05-22 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
| SK287073B6 (sk) | 1998-06-30 | 2009-11-05 | Om Pharma | N-Acyldipeptidový derivát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje |
| JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法 |
| US5962636A (en) | 1998-08-12 | 1999-10-05 | Amgen Canada Inc. | Peptides capable of modulating inflammatory heart disease |
| WO2000014217A2 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
| WO2000023955A1 (en) | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
| MXPA01005389A (es) | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| MXPA01006491A (es) | 1998-12-23 | 2003-06-06 | Thompson Boyce Plant Res | Expresion de antigenos de superficie de hepatitis b inmunogenicos en plantas transgenicas. |
| EP1141314A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP2003520568A (ja) | 1999-02-02 | 2003-07-08 | バイオカシェ ファーマシューティカルズ， インコーポレイテッド | 高度な抗原提示プラットフォーム |
| IL145025A0 (en) | 1999-02-25 | 2002-06-30 | Smithkline Beecham Biolog | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
| WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
| WO2000054803A2 (en) | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| ES2250151T3 (es) | 1999-06-29 | 2006-04-16 | Glaxosmithkline Biologicals S.A. | Uso de cpg como adyuvante de vacuna contra vih. |
| US7479285B1 (en) | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| AU6801800A (en) | 1999-08-30 | 2001-03-26 | Ludwig Institute For Cancer Research | Isolated nona and decapeptides which bind to hla molecules, and the use thereof |
| JP2001151698A (ja) | 1999-09-10 | 2001-06-05 | Nichiko Pharmaceutical Co Ltd | インフルエンザワクチン |
| WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| IL148844A0 (en) | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| ATE454901T1 (de) | 1999-10-13 | 2010-01-15 | Novartis Vaccines & Diagnostic | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| WO2001038358A2 (en) | 1999-11-24 | 2001-05-31 | Chiron Corporation | Hbv/hcv virus-like particle |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| EP1261366A4 (en) | 2000-02-24 | 2003-06-18 | Univ Leland Stanford Junior | ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS |
| EP1278542A2 (en) | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
| AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
| AU2002248185A1 (en) | 2000-12-14 | 2002-07-16 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
| WO2003031466A2 (en) | 2001-10-05 | 2003-04-17 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| US20030050268A1 (en) | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| WO2003040308A2 (en) | 2001-07-27 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| AU2002346960A1 (en) | 2001-10-06 | 2003-04-22 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
| DE60230656D1 (de) | 2001-11-07 | 2009-02-12 | Cytos Biotechnology Ag | Antigenraster welche il-5, il-13 oder eotaxin präshilen erkrankungen |
| KR20050044316A (ko) | 2001-11-07 | 2005-05-12 | 사이토스 바이오테크놀로지 아게 | 호산구성 알레르기 질환 치료용의 ｉｌ-5, ｉｌ-13 또는에오탁신을 제시하는 항원 어레이 |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US20030219459A1 (en) | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
| AU2003205623A1 (en) | 2002-01-18 | 2003-07-30 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
| ATE489969T1 (de) | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| AU2003246690B2 (en) | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
| RU2325202C2 (ru) | 2002-07-19 | 2008-05-27 | Цитос Байотекнолоджи Аг | Конъюгаты грелин-носитель |
| US8575110B2 (en) | 2003-02-17 | 2013-11-05 | Alpha-O Peptides G | Peptidic nanoparticles as drug delivery and antigen display systems |
| CN101675993A (zh) * | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
| AU2004255470B2 (en) * | 2003-07-10 | 2010-08-19 | Cytos Biotechnology Ag | Packaged virus-like particles |
| WO2005014110A1 (en) | 2003-07-22 | 2005-02-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| NZ546275A (en) | 2003-10-30 | 2009-05-31 | Coley Pharm Gmbh | C-class oligonucleotides analogs with enhanced immunostimulatory potency |
| CN102895663A (zh) | 2004-04-14 | 2013-01-30 | 健泰科生物技术公司 | 含有用于调节血管发育的egfl7拮抗剂的组合物及方法 |
| KR20070058426A (ko) | 2004-06-02 | 2007-06-08 | 사이토스 바이오테크놀로지 아게 | 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도 |
| DE102004041340A1 (de) | 2004-08-20 | 2006-02-23 | Deutsche Gelatine-Fabriken Stoess Ag | Nanopartikel und Verfahren zu deren Herstellung |
| NZ554387A (en) * | 2004-09-21 | 2009-09-25 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| ES2424229T3 (es) | 2005-03-18 | 2013-09-30 | Cytos Biotechnology Ag | Proteínas de fusión de alérgenos de gato y utilización de las mismas |
| ATE515566T1 (de) | 2005-05-26 | 2011-07-15 | Cytos Biotechnology Ag | Skalierbares fermentationsverfahren |
| BRPI0616446A2 (pt) | 2005-09-28 | 2011-06-21 | Cytos Biotechnology Ag | composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento |
| AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| SI2032592T1 (sl) | 2006-06-12 | 2013-10-30 | Cytos Biotechnology Ag | Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov |
| JP5396809B2 (ja) | 2008-10-17 | 2014-01-22 | ソニー株式会社 | 固体撮像装置、カメラ、および、固体撮像装置の製造方法 |
-
2007
- 2007-06-12 SI SI200731307T patent/SI2032592T1/sl unknown
- 2007-06-12 RU RU2008151507/10A patent/RU2476595C2/ru active
- 2007-06-12 NZ NZ573622A patent/NZ573622A/en unknown
- 2007-06-12 BR BRPI0713651-0A patent/BRPI0713651B1/pt active IP Right Grant
- 2007-06-12 MX MX2008015529A patent/MX2008015529A/es active IP Right Grant
- 2007-06-12 ES ES12167784T patent/ES2738986T3/es active Active
- 2007-06-12 DK DK07764627.1T patent/DK2032592T3/da active
- 2007-06-12 AU AU2007260236A patent/AU2007260236B2/en active Active
- 2007-06-12 PT PT77646271T patent/PT2032592E/pt unknown
- 2007-06-12 SG SG2011042470A patent/SG172696A1/en unknown
- 2007-06-12 EP EP12167784.3A patent/EP2530086B1/en active Active
- 2007-06-12 JP JP2009514696A patent/JP5437797B2/ja active Active
- 2007-06-12 PL PL07764627T patent/PL2032592T3/pl unknown
- 2007-06-12 CA CA2655108A patent/CA2655108C/en active Active
- 2007-06-12 ES ES07764627T patent/ES2427994T3/es active Active
- 2007-06-12 US US12/304,620 patent/US8541559B2/en active Active
- 2007-06-12 WO PCT/EP2007/005188 patent/WO2007144150A1/en not_active Ceased
- 2007-06-12 KR KR1020097000353A patent/KR101552227B1/ko active Active
- 2007-06-12 EP EP07764627.1A patent/EP2032592B1/en active Active
- 2007-06-12 CN CN2007800219182A patent/CN101466720B/zh active Active
-
2008
- 2008-11-26 IL IL195526A patent/IL195526A/en active IP Right Grant
- 2008-11-27 ZA ZA2008/10109A patent/ZA200810109B/en unknown
-
2013
- 2013-07-15 US US13/942,483 patent/US9404126B2/en active Active
- 2013-07-18 US US13/945,708 patent/US9902972B2/en active Active
- 2013-12-11 JP JP2013255691A patent/JP6057882B2/ja active Active
-
2018
- 2018-01-16 US US15/872,594 patent/US10358656B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2476595C2 (ru) | Способы упаковки олигонуклеотидов в вирусоподобные частицы рнк-содержащих бактериофагов | |
| JP2009539907A5 (enExample) | ||
| JP2014097057A5 (enExample) | ||
| EP4599067A1 (en) | Artificial polynucleotides for expressing proteins | |
| JP2021525058A (ja) | ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化 | |
| JP2023546997A (ja) | 熱及び酵素加水分解に対する耐性の増加を示す重水素安定化リボ核酸（ｒｎａ）分子、安定化ｒｎａ分子を含む水性組成物、及びその製造方法 | |
| JP2023505188A (ja) | 核酸組成物 | |
| EP4136232A1 (en) | Decoy transcripts for treatment of ssrna viral infection | |
| CN113462699A (zh) | 一种利用大肠杆菌表达猫细小vp2蛋白自主组装病毒样颗粒的制备 | |
| AU2013204383B2 (en) | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages | |
| CN1135264C (zh) | 制备L-甲硫氨酸γ-裂合酶晶体的方法 | |
| CN117296837B (zh) | 一种防治烟草花叶病毒的手性碳纳米材料及其制备方法与应用 | |
| CN112279899A (zh) | 一种纯化原核表达蛋白的方法 | |
| CN121737132A (zh) | 一种用于防治柑橘全爪螨的dsRNA纳米颗粒复合物、制备方法与应用 | |
| CN121065173A (zh) | 用于改善mRNA产生的组合物和方法 | |
| RU2020131771A (ru) | Упаковка олигонуклеотидов в вирусоподобные частицы | |
| Kumar et al. | Cloning of 6.5 kb segment of cell culture adapted classical swine fever virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |